International Journal of Risk & Safety in Medicine - Volume 9, issue 1
Purchase individual online access for 1 year to this journal.
Price: EUR 155.00
Impact Factor 2023: 1.7
The International Journal of Risk and Safety in Medicine is concerned with rendering the practice of medicine as safe as it can be; that involves promoting the highest possible quality of care, but also examining how those risks which are inevitable can be contained and managed.
This is not exclusively a drugs journal. Recently it was decided to include in the subtitle of the journal three items to better indicate the scope of the journal, i.e. patient safety, pharmacovigilance and liability and the Editorial Board was adjusted accordingly. For each of these sections an Associate Editor was invited. We especially want to emphasize patient safety. Our journal wants to publish high quality interdisciplinary papers related to patient safety, not the ones for domain specialists. For quite some time we have also been devoting some pages in every issue to what we simply call WHO news. This affinity with WHO underlines both the International character of the journal and the subject matter we want to cover. Basic research, reports of clinical experience and overviews will all be considered for publication, but since major reviews of the literature are often written at the invitation of the Editorial Board it is generally advisable to consult with the Editor in advance. Submission of news items will be appreciated, as will be the contribution of letters on topics which have been dealt with in the journal.
Abstract: Concern over the safety of triazolam is reflected in the actions taken against the drug world-wide by many drug regulatory agencies, ranging from restrictions in duration of use and dosage to banning of the drug. There is extensive scientific literature documenting that triazolam produces frequent and severe psychiatric adverse events: during drug administration these include memory impairment/amnesia and other cognitive impairments and daytime anxiety states and early morning insomnia; following drug withdrawal there can be a marked worsening of sleep (rebound insomnia). It is difficult to improve triazolam's benefit-to-risk ratio either by lowering the dose or by short and…intermittent use. The 0.5 mg and 1.0 mg doses of triazolam are effective, but produce severe psychiatric adverse events while the 0.25 mg dose has limited efficacy while still being associated with frequent adverse events. Moreover, many of triazolam's adverse events are associated with the first (or first several) doses used, and rebound insomnia often occurs on withdrawal even after only one night of use.
Abstract: The accuracy of data contained in the Danish vascular database was compared with the case notes. A total of 100 case notes were reviewed for 11 pertinent variables in the database. A high error rate ranging from 2 to 34% was found. Also, approximately 10% of patients had never been entered into the vascular database. Further improvement of the Danish vascular database is necessary for its use as basis for reporting results.
Abstract: The Maltese population has been repeatedly shown to have high mean blood lead levels irrespective of age. This study confirms that these higher levels also occur in Maltese children. A definite correlation is shown between high blood lead levels and the environment of the subjects studied, being statistically higher in individuals living on the urbanized larger island. A statistical correlation has been shown between hand-wipe specimens taken from children playing in a playground and the traffic density of the area. A similar statistical correlation between playground, street and household dust to traffic density has also been identified.
Abstract: Eleven plaintiffs vs. The United Kingdom Medical Research Council (First Defendant) and the Secretary of State of Health (Second Defendant). High Court of Justice, Queen's Bench Division, No. 1994-N-06806. Judgement by Mr. Justice Morland, London; unrevised text, July 24th, 1996.
Keywords: Human Growth Hormone, contamination, Creutzfeldt-Jakob disease, negligence, liability of the state, emergent knowledge